四种降压药物血压反应的异质性:一项随机临床试验
在瑞典门诊研究诊所开展随机双盲重复交叉试验,纳入低心血管风险1级高血压患者,比较赖诺普利、坎地沙坦、氢氯噻嗪和氨氯地平四种降压药。完成1468个治疗周期(中位56天),270/280名随机参与者完成。个体间对不同药物的血压反应差异显著,个性化治疗平均可额外降低收缩压4.4 mm Hg。
要点
- 个体间对赖诺普利与氢氯噻嗪、赖诺普利与氨氯地平、坎地沙坦与氢氯噻嗪、坎地沙坦与氨氯地平的血压反应差异显著(P < .001)。
- 赖诺普利与坎地沙坦、氢氯噻嗪与氨氯地平之间的大差异被排除。
- 个性化治疗平均可额外降低日间收缩压4.4 mm Hg。
核心结论
- 高血压药物治疗的血压反应存在显著异质性,该发现可能对个性化治疗有启示。
研究设计与样本
- 随机双盲重复交叉试验,在瑞典门诊研究诊所纳入低心血管风险1级高血压男性和女性。
- 280名参与者随机分组,270名完成,共记录1468个完成治疗周期(中位长度56天)。
- 参与者按随机顺序接受4类降压药治疗:赖诺普利(血管紧张素转换酶抑制剂)、坎地沙坦(血管紧张素受体阻滞剂)、氢氯噻嗪(噻嗪类)、氨氯地平(钙通道阻滞剂),其中2类重复治疗。
- 采用混合效应模型评估个体对某种治疗反应优于另一种的程度,并估计个性化治疗可额外实现的血压降低。
主要发现
- 不同治疗的血压反应在个体间差异显著(P < .001),具体见于赖诺普利与氢氯噻嗪、赖诺普利与氨氯地平、坎地沙坦与氢氯噻嗪、坎地沙坦与氨氯地平的选择。
- 赖诺普利与坎地沙坦、氢氯噻嗪与氨氯地平的选择中,大差异被排除。
- 平均而言,个性化治疗有潜力额外降低收缩压4.4 mm Hg。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hypertension is the leading risk factor for premature death worldwide. Multiple blood pressure-lowering therapies are available but the potential for maximizing benefit by personalized targeting of drug classes is unknown. OBJECTIVE: To investigate and quantify the potential for targeting specific drugs to specific individuals to maximize blood pressure effects. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, repeated crossover trial in men and women with grade 1 hypertension at low risk for cardiovascular events at an outpatient research clinic in Sweden. Mixed-effects models were used to assess the extent to which individuals responded better to one treatment than another and to estimate the additional blood pressure lowering achievable by personalized treatment. INTERVENTIONS: Each participant was scheduled for treatment in random order with 4 different classes of blood pressure-lowering drugs (lisinopril [angiotensin-converting enzyme inhibitor], candesartan [angiotensin-receptor blocker], hydrochlorothiazide [thiazide], and amlodipine [calcium channel blocker]), with repeated treatments for 2 classes. MAIN OUTCOMES AND MEASURES: Ambulatory daytime systolic blood pressure, measured at the end of each treatment period. RESULTS: There were 1468 completed treatment periods (median length, 56 days) recorded in 270 of the 280 randomized participants (54% men; mean age, 64 years). The blood pressure response to different treatments varied considerably between individuals (P < .001), specifically for the choices of lisinopril vs hydrochlorothiazide, lisinopril vs amlodipine, candesartan vs hydrochlorothiazide, and candesartan vs amlodipine. Large differences were excluded for the choices of lisinopril vs candesartan and hydrochlorothiazide vs amlodipine. On average, personalized treatment had the potential to provide an additional 4.4 mm Hg-lower systolic blood pressure. CONCLUSIONS AND RELEVANCE: These data reveal substantial heterogeneity in blood pressure response to drug therapy for hypertension, findings that may have implications for personalized therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02774460.
引用
- Sundström J, Lind L, Nowrouzi S, et al. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. JAMA. 2023. PMID: 37039792. doi:10.1001/jama.2023.3322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。